TP53 and prostate carcinoma: Reports from a recent study reveal that CAPE blocks the expression of the MALT1 gene to decrease the cell proliferation, invasion, and tumor growth of prostate carcinoma cells via the p53 and NF-κB signaling pathways, and they further verify that CAPE is an effective antitumor agent for human androgen-dependent and androgen-independent prostate carcinoma cells by inhibiting MALT1 expression in vitro and in vivo [80].